Advertisement
Advertisement
U.S. Markets close in 2 hrs 47 mins
Advertisement
Advertisement
Advertisement
Advertisement

DBV Technologies S.A. (DBVT)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
1.4150-0.0150 (-1.05%)
As of 04:00PM EDT. Market open.
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close1.4300
Open1.4000
Bid1.3900 x 1300
Ask1.4200 x 1300
Day's Range1.3800 - 1.4150
52 Week Range1.1500 - 6.4700
Volume24,195
Avg. Volume291,581
Market Cap159.875M
Beta (5Y Monthly)2.04
PE Ratio (TTM)N/A
EPS (TTM)-1.1260
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est6.99
  • GlobeNewswire

    Monthly information regarding the total number of voting rights and total number of shares of the Company as of April 30, 2022

    Monthly information regarding the total number of voting rights and total number of shares of the Company as of April 30, 2022 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers) Market : NYSE Euronext Paris ISIN Code: FR 0010417345 Date Total number of shares Total number of voting rights04/30/202255,095,537 Total gross of voting rights: 55,095,537 Total net* of voting rights: 54,920,329 * Total net = total number of voting rights attached to shares – shares witho

  • GlobeNewswire

    DBV Technologies Announces Results of Its 2022 Ordinary and Extraordinary General Meeting

    Montrouge, France, May 12, 2022 DBV Technologies Announces Results of Its 2022 Ordinary and Extraordinary General Meeting Shareholders Approved All Proposed Resolutions DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today held its Ordinary and Extraordinary General Meeting. The General Meeting was chaired by Michel de Rosen, Chairman of DBV Technologies. The Company’s shareholders approved all resolutions submitted b

  • GlobeNewswire

    DBV Technologies Completes ADSs Sale of an amount of $15.3 million on Nasdaq through its At-The-Market program (ATM)

    Montrouge, France, May 5, 2022 DBV Technologies Completes ADSs Sale of an amount of $15.3 million on Nasdaq through its At-The-Market program (ATM) DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Global Select Market: DBVT) (the “Company”), a clinical-stage biotechnological company, today announced that, pursuant to the Company’s At-The-Market program established on May 2, 2022 (the “ATM Program”), it has issued and completed sales of new ordinary shares (the “Ordinary Shares”) in

Advertisement
Advertisement